Background：Farletuzumab MORAb-003 is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 Teng, Xie, Teng, & Lee, 2012. In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts Teng et al., 2012. Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months Konner et al., 2010. Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer Walters et al., 2013. The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer PSOC, defined as a PFI of ≥ 6 months, in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study ClinicalTrials.gov Identifier: NCT02631876 was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial ClinicalTrials.gov Identifier: NCT02019524 for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial NCT02764333 is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 also called TPIV200, a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab MEDI4736.
Alternative Names：M3, MORAb-003, MORAb-003-VCP-eribulin, MORAb-202,
